"NPS+ Renal Cell Carcinoma (EU5)" is now available at Fast Market Research

Compare 8 major RCC brands. Learn which one scores 6 times higher than any other?

FirstView's NPS+ Renal Cell Carcinoma report compares brand loyalty for 8 major RCC treatments-information you can use to improve your brand's health, and boost your market share. /paragraph>Based on your brand's net promoter score (NPS), the report shows you how likely doctors are to recommend your brand, which of your competitors they recommend, and which promotional messages drive those recommendations. Plus you'll learn how doctors really perceive your brand./paragraph>Based on your brand's net promoter score (NPS), the report shows you how likely doctors are to recommend your brand, which of your competitors they recommend, and which promotional messages drive those recommendations. Plus you'll learn how doctors really perceive your brand./Paragraph>Intuitive, easy to use KPIs highlight areas for improvement and make your next steps crystal clear./Paragraph>Interested in the US market? Click here to see the US Edition./Paragraph>Find out How Doctors View Renal Cell Carcinoma Drug Brands

Full Report Details at
- http://www.fastmr.com/prod/1152009_nps+_renal_cell_carcinoma_eu5.aspx?afid=301

* Afinitor (everolimus; Novartis): Does Afinitor's route of administration or benefit/risk profile drive more recommendations?
* Avastin (bevacizumab; Roche): How important is cost to Avastin Promoters?
* Inlyta (axitinib; Pfizer): Which leading brand's Detractors are most likely to promote Inlyta?
* Opdivo (nivolumab; Bristol-Myers Squibb): Oncologists associate Opdivo with a novel mechanism of action. Does that drive the most recommendations?
* Proleukin (aldesleukin; Prometheus): What does Proleukin's brand DNA reveal about why Detractors won't recommend it?
* Sutent (sunitinib malate; Pfizer): More than 90% of Sutent Promoters also promote one brand. Which one?
* Torisel (temsirolimus; Pfizer): Which EU5 countries' oncologists had the most positive comments about Torisel?
* Votrient (pazopanib; Novartis): Is slowing disease progression or reducing relapses a more effective brand message among Votrient Promoters?

Top Takeaways

* NPS scores show a clear market leader: Only three surveyed brands have a positive NPS, but the leading brand's score is nearly six times that of its nearest competitor.
* Satisfaction moderate, lower than in US: Fewer than 65% of oncologists surveyed are satisfied with available RCC drugs. In the US, the figure is over 70%.
* Exclusivity is relatively high: More than 20% of oncologists surveyed promote one brand exclusively.
* Cost is a low priority: For all but one surveyed brand, clinical attributes drive recommendations far more than cost concerns.
* One brand has the potential for massive market share gain: Twice as much as any other surveyed brand if it can turn its Detractors into Promoters.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- NPS+ Renal Cell Carcinoma (US)
- Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2015
- Renal Cell Carcinoma - Pipeline Review, H2 2015
- Metastatic Renal Cell Carcinoma - Pipeline Review, H1 2016
- Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2015